Sumeet K Mittal1, Joe Abdo2, Malika P Adrien3, Binyam A Bayu3, Jay R Kline3, Molly M Sullivan3, Devendra K Agrawal4. 1. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Dignity Health, Phoenix, AZ, USA. 2. Stella Diagnostics, Inc., Salt Lake City, UT, USA. 3. Department of Biochemistry, Georgetown University Medical Center, Washington, DC, USA. 4. Department of Translational Research, Western University of Health Sciences, Pomona, CA, USA.
Abstract
OBJECTIVE: Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), which has one of the lowest 5-year survival rates in oncology. The reasons for poor survival are twofold: the large majority of diagnoses are in advanced stages (~80%) and limited treatment options, with a deficit of biology-guided therapies. As a rapidly growing public health concern with poor prognosis, research into the molecular progression for BE and novel therapeutics for EAC currently has high clinical utility. Review of the literature reveals that innovative analysis of metaplastic progression from BE to EAC at a molecular level can shed light on the underlying transformative probabilities of BE into malignant pathologies and may impact current of future therapeutic modalities for management of these diseases. BACKGROUND: EAC is the fastest increasing cancer in the United States with a 600% increase over the past 25 years. This cancer arises from dysplastic tissue of BE, a complication of gastroesophageal reflux disease (GERD). Chronic acid and bile reflux in the distal esophagus initiates a metaplastic conversion of normal squamous epithelium to premalignant intestinalized columnar epithelium. Patients with BE have a 125-fold higher risk of cancer compared to the general population. METHODS: We critically reviewed the current status of BE monitoring, and subsequent therapeutic strategies being used in patients who have progressed to cancer. Also, new diagnostic tools and therapeutic candidates for BE-related EAC are discussed. Highly-targeted searches of databases containing recent original peer-reviewed papers were utilized for this review. CONCLUSIONS: Novel and well-described biomarkers analyzed in the patient's diseased tissue will provide for more powerful diagnostics, but also possess the potential to develop strategies for personalized management and identify targets for intervention to either cease disease progression or treat BE and/or EAC. Since millions of Americans develop BE without progressing to cancer, there is a critical need to identify the small percentage of Barrett's patients who possess hallmarks of disease progression or carcinogenesis with novel screening techniques. Incorporation of such tools into standard screening protocols for BE surveillance and/or therapy would be critical to detect malignant transformations before clinically obvious cancer ever develops. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
OBJECTIVE: Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), which has one of the lowest 5-year survival rates in oncology. The reasons for poor survival are twofold: the large majority of diagnoses are in advanced stages (~80%) and limited treatment options, with a deficit of biology-guided therapies. As a rapidly growing public health concern with poor prognosis, research into the molecular progression for BE and novel therapeutics for EAC currently has high clinical utility. Review of the literature reveals that innovative analysis of metaplastic progression from BE to EAC at a molecular level can shed light on the underlying transformative probabilities of BE into malignant pathologies and may impact current of future therapeutic modalities for management of these diseases. BACKGROUND: EAC is the fastest increasing cancer in the United States with a 600% increase over the past 25 years. This cancer arises from dysplastic tissue of BE, a complication of gastroesophageal reflux disease (GERD). Chronic acid and bile reflux in the distal esophagus initiates a metaplastic conversion of normal squamous epithelium to premalignant intestinalized columnar epithelium. Patients with BE have a 125-fold higher risk of cancer compared to the general population. METHODS: We critically reviewed the current status of BE monitoring, and subsequent therapeutic strategies being used in patients who have progressed to cancer. Also, new diagnostic tools and therapeutic candidates for BE-related EAC are discussed. Highly-targeted searches of databases containing recent original peer-reviewed papers were utilized for this review. CONCLUSIONS: Novel and well-described biomarkers analyzed in the patient's diseased tissue will provide for more powerful diagnostics, but also possess the potential to develop strategies for personalized management and identify targets for intervention to either cease disease progression or treat BE and/or EAC. Since millions of Americans develop BE without progressing to cancer, there is a critical need to identify the small percentage of Barrett's patients who possess hallmarks of disease progression or carcinogenesis with novel screening techniques. Incorporation of such tools into standard screening protocols for BE surveillance and/or therapy would be critical to detect malignant transformations before clinically obvious cancer ever develops. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Barrett’s esophagus (BE); early cancer detection; esophageal adenocarcinoma (EAC); precision oncology; targeted therapy
Authors: Chaitan K Narsule; Miguel A Burch; Michael I Ebright; Donald T Hess; Roberto Rivas; Benedict D T Daly; Hiran C Fernando Journal: J Thorac Cardiovasc Surg Date: 2011-11-08 Impact factor: 5.209
Authors: Erik J Snider; Griselda Compres; Daniel E Freedberg; Hossein Khiabanian; Yael R Nobel; Stephania Stump; Anne-Catrin Uhlemann; Charles J Lightdale; Julian A Abrams Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-29 Impact factor: 4.254
Authors: Puya Gharahkhani; Rebecca C Fitzgerald; Thomas L Vaughan; Claire Palles; Ines Gockel; Ian Tomlinson; Matthew F Buas; Andrea May; Christian Gerges; Mario Anders; Jessica Becker; Nicole Kreuser; Tania Noder; Marino Venerito; Lothar Veits; Thomas Schmidt; Hendrik Manner; Claudia Schmidt; Timo Hess; Anne C Böhmer; Jakob R Izbicki; Arnulf H Hölscher; Hauke Lang; Dietmar Lorenz; Brigitte Schumacher; Andreas Hackelsberger; Rupert Mayershofer; Oliver Pech; Yogesh Vashist; Katja Ott; Michael Vieth; Josef Weismüller; Markus M Nöthen; Stephen Attwood; Hugh Barr; Laura Chegwidden; John de Caestecker; Rebecca Harrison; Sharon B Love; David MacDonald; Paul Moayyedi; Hans Prenen; R G Peter Watson; Prasad G Iyer; Lesley A Anderson; Leslie Bernstein; Wong-Ho Chow; Laura J Hardie; Jesper Lagergren; Geoffrey Liu; Harvey A Risch; Anna H Wu; Weimin Ye; Nigel C Bird; Nicholas J Shaheen; Marilie D Gammon; Douglas A Corley; Carlos Caldas; Susanne Moebus; Michael Knapp; Wilbert H M Peters; Horst Neuhaus; Thomas Rösch; Christian Ell; Stuart MacGregor; Paul Pharoah; David C Whiteman; Janusz Jankowski; Johannes Schumacher Journal: Lancet Oncol Date: 2016-08-12 Impact factor: 41.316